NCT04653844

Brief Summary

The SARS-Cov2 pandemic remains associated with many concerns. One of the them is the real frequency of likely re-infection and subsequently the level of protection conferred by the acquired immunity following primary-infection. We propose to analyze a large set of laboratory data produced since the early beginning of the SARS-Cov2 spread in the French population to identify recurrent infection events and, more generally, gain insight about infection kinetics.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
7,000,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2020

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

December 3, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 4, 2020

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2023

Completed
Last Updated

January 4, 2022

Status Verified

January 1, 2022

Enrollment Period

2.9 years

First QC Date

December 3, 2020

Last Update Submit

January 3, 2022

Conditions

Covid-19SARS-CoV Infection

Keywords

SARS-Cov2 infectionPositive SARS-Cov2 RT-PCRSARS-Cov2 immune statusreinfectionkineticsRt-PCRimmunity

Outcome Measures

Primary Outcomes (1)

  • SARS-CoV-2 reinfection rate

    SARS-CoV-2 reinfection rate

    1 day

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

French population with a positive SARS-Cov2 diagnosis documented through a positive RT-PCR result

You may qualify if:

  • \- People with at least one positive SARS-Cov2 RT-PCR result with a known sampling date

You may not qualify if:

  • \- Patient refusing to participate in research

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Uh Montpellier

Montpellier, 34295, France

RECRUITING

MeSH Terms

Conditions

COVID-19Severe Acute Respiratory SyndromeReinfection

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesRecurrenceDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Vincent Foulongne, PhD

    UH MONTPELLIER

    STUDY DIRECTOR

Central Study Contacts

Samuel Alizon, PhD

CONTACT

610654902samuel.alizon@cnrs.fr

Vincent Foulongne, PhD

CONTACT

467 330 254v-foulongne@chu-montpellier.fr

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2020

First Posted

December 4, 2020

Study Start

February 1, 2020

Primary Completion

December 31, 2022

Study Completion

January 30, 2023

Last Updated

January 4, 2022

Record last verified: 2022-01

Locations

FR(1)